Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis

New England Journal of Medicine

Volumn 357, Issue 1, 2007, Pages 28-38

  Home, Philip D ^a,i   Pocock, Stuart J ^b   Beck Nielsen, Henning ^c   Gomis, Ramón ^d   Hanefeld, Markolf ^e   Jones, Nigel P ^f   Komajda, Michel ^g   McMurray, John J V ^h  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY OF BARCELONA   (Spain)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f GLAXOSMITHKLINE   (United Kingdom)

^g SORBONNE UNIVERSITÉ   (France)

^h UNIVERSITY OF GLASGOW   (United Kingdom)

ⁱ NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; INSULIN; METFORMIN; METFORMIN PLUS ROSIGLITAZONE; ROSIGLITAZONE; SULFONYLUREA;

ADD ON THERAPY; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SCREENING; FEMALE; FOLLOW UP; GLYCEMIC CONTROL; HAZARD RATIO; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL ANALYSIS; SUDDEN DEATH; TREATMENT OUTCOME;

EID: 34250865768     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa073394     Document Type: Article

References (18)

1. Panzram G. Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1987;30:123-31. [Erratum, Diabetologia 1987;30:364.]
2. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Interventional Trial. Diabetes Care 1993;16:434-44.
3. Collins R, Armitage J, Parish S, Sleight P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003;361:2005-16.
4. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
5. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population: sixteen year follow-up study. Diabetes 1974;23:105-11.
6. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia 2005;48:1726-35.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-53. [Erratum, Lancet 1999;354:602.]
8. Idem. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65. [Erratum, Lancet 1998;352:1558.]
9. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356:2457-71.
10. Definition WHO. Diagnosis and Classification of Diabetes Mellitus and its Complications. Document no. WHO/NCD/NCS/99.2. Geneva: World Health Organization, 1999.
11. Psaty BM, Furberg CD. Rosiglitazone and cardiovascular risk. N Engl J Med 2007;356:2522-4.
12. Krall RL. Cardiovascular safety of rosiglitazone. Lancet (in press).
13. Home PD, Jones NP, Pocock SJ, et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 2007;24:626-34.
14. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849-61. [Errata, Lancet 2006;368:1415, 2006;368:1420.]
15. IDF Clinical Guidelines Task Force. Global guideline for type 2 diabetes. Brussels: International Diabetes Federation, 2005. (Accessed June 8, 2007, at http://www.idf.org/home/index.cfm?unode=B7462CCB-3A4C-472C-80E4-710074D74AD3.)
16. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005;366:1279-89.
17. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-43. [Erratum, N Engl J Med 2007;356:1387-8.]
18. Wittes J, Palensky J, Asner D, et al. Experience collecting interim data on mortality: an example from the RALES study. Curr Control Trials Cardiovasc Med 2001;2:59-62.